Parte, Capitolo, Paragrafo

 1 I, 1,1(8)   |             Arch. Allergy Immunol., 1998, 116:5-21. ~
 2 I, 1,1(9)   |             Arch. Allergy Immunol., 1998, 116:5-21; Cooper D.K.C,
 3 I, 1,1(10)  |          transplants. J Clin Invest 1998; 101:1745-1756. ~
 4 I, 1,1(11)  |           feasible?, J Am Coll Surg 1998, 186(4):383-7. ~
 5 I, 1,1(12)  |  transplantation, Annu.Rev.Immunol. 1998, 16:433-70. ~
 6 I, 2,2(22)  |      rejection, Xenotransplantation 1998, 5:169-175. ~
 7 I, 2,2(24)  |             prospects, Annu.Rev.Med.1998, 49:301-10. ~
 8 I, 2,2(26)  |  transplantation, Annu.Rev.Immunol. 1998, 16:433-70. ~
 9 I, 2,4(40)  | xenotransplantation, Ann NY Acad Sc 1998, 862:121-124. ~
10 I, 2,5(45)  |        therapy, Curr Opin Chem Biol 1998, 2:512-8. ~
11 II, 1,11(62)|         Storia e attualità, Med Mor 1998, 48: 15-46. ~
12 II, 2,12(65)|   Collective Risk, Nature Medicine, 1998, 4: 141-144; Hughes J.,
13 II, 2,12(65)|          Journal of Medical Ethics, 1998, 24: 18-24; Vanderpool H.
14 II, 2,12(65)|        Xenotransplants, The Lancet, 1998, 351: 1347-1350; Clark M.A.,
15 II, 2,17(72)|    economics, Food Drug Law Journal 1998, 53 (2):353-384; Urruela
16 II, 2,18(74)|           Law International, London 1998: 145-150; Accordo di Marrakech